Imatinib Mesylate as First-line Therapy in Patients with Chronic Myeloid Leukemia Philadelphia + (CML-PH+) in Accelerated Phase (AP), Comparison with Chronic Phase. A Long Term Retrospective Study
Accelerated phase (AP), is a progression state of CML. Treatment options varies; however in our institution, Imatinib Mesylate [(IM) Glivec ® Novartis, Mexico] is the only first line treatment avilable and the long-term outcome information is scarce in comparation with Chronic Phase (CP) CML
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Berenice Vicente-Hernandez, Rafael Hurtado-Monroy, Diego Sarre-Alvarez, Pablo Vargas-Viveros, Montserrat Rojas, Carlos Best, Judith Cruz-Vazquez, Myrna Candelaria-Hernandez Tags: Chronic Myelogenous Leukemia Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Hematology | Leukemia | Lymphoma | Myeloma | Study